Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy

Published:2016-09-09 Issue:11 Volume:23 Page:1886-1896
ISSN:1350-9047
Container-title:Cell Death & Differentiation
language:en
Short-container-title:Cell Death Differ

Author:

Wang Junjian,Wang Haibin,Wang Ling-Yu,Cai Demin,Duan Zhijian,Zhang Yanhong,Chen Peng,Zou June X,Xu Jianzhen,Chen Xinbin,Kung Hsing-Jien,Chen Hong-Wu

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology

Link

http://www.nature.com/articles/cdd201692.pdf

Reference56 articles.

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155–162.

2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157–163.

3. Pan G, Ni J, Wei Y-F, Yu G-l, Gentz R, Dixit VM . An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815–818.

4. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141–143.

5. de Miguel D, Lemke J, Anel A, Walczak H, Martinez-Lostao L . Onto better TRAILs for cancer treatment. Cell Death Differ 2016; 23: 733–747.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential drug targets for prostate cancer ： A mendelian randomization study and application for target-derived drug design;2024-09-02

2. The mitochondrial protease ClpP is a druggable target that controls VSMC phenotype by a SIRT1-dependent mechanism;Redox Biology;2024-07

3. The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities;Genes & Diseases;2024-03

4. Targeting epigenetic regulators to overcome drug resistance in cancers;Signal Transduction and Targeted Therapy;2023-02-17

5. Zinc finger myeloid Nervy DEAF-1 type (ZMYND) domain containing proteins exert molecular interactions to implicate in carcinogenesis;Discover Oncology;2022-12-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3